John P. Leonard, M.D.

Medical Oncology

Publications

Partial Listing 

Leonard JP, May WS, Ihle JN, Pettit GR, Sharkis SJ. Regulation of hematopoiesis IV: The role of interleukin-3 and bryostatin in the growth of erythropoietic progenitors from normal and anemic W/Wv mice. Blood, 1988;72:1492-1496.

 

Sharkis SJ, Leonard JP, Ihle JN, May WS. The effects of interleukin-3, bryostatin and thymocytes on erythropoiesis. NY Acad Sci,1989;554:59-65.

 

Moore MAS, Leonard JP, Flasshove M, Bertino J, Gallardo H, Sadelain M. Gene therapy - the challenge for the future. Ann Oncol,1996;7(S2):53-58.

 

Flasshove M, Banerjee D, Leonard JP, Mineishi S, Li M.-X, Bertino JR. and Moore MAS. Retroviral transduction of human CD34 umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA. Hum Gene Ther, 1998;9:63-71.

 

Coleman M. Kauffmann T, Nisce LZ, Leonard JP. Treatment of non-

laparotomized (clinical) stage I and II Hodgkin’s disease patients by extended field and splenic irradiation. Int J Rad Oncol Biol Phys, 2000;46:1235-1238.

 

Flasshove M, Leonard JP, Bardenheuer W, Moore MAS. Increased resistance and selection in paclitaxel for peripheral blood progenitor cells following transduction with the MDR1 gene. TumorDiagnostik and Therapie (German), 2000;21:51-58.

 

Coleman M, Leonard JP, Schuster MW, Kaufman TP. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin’s lymphoma. Eur J Haematol 2001;66(S1):41-45.

 

Leonard JP, Schattner EJ, Coleman M. Biology and treatment of mantle cell lymphoma, Curr Opin Oncol, 2001;13:342-347.

 

Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard JP, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Knox SJ, Vose JM. Pivotal study of BexxarÔ (Iodine I 131 Tositumomab) for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas, J Clin Oncol, 2001;19(19):3918-3928.

 

Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J. Immunotherapy of Non-Hodgkin’s Lymphomas, Hematology (Am Soc Hematol Educ Program), 2001:221-240.

 

Leonard JP and Link BK. Immunotherapy of NHL with Epratuzumab (anti-CD22) and Hu1D10, Semin Oncol, 2002;29(1S2):81-86.

 

Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma, Cancer, 2002;94(4):879-888

 

Coleman M, Leonard J, Lyons L, Pekle K, Nahum K, Pearse R, Niesvizky and Michaeli J. BLT-D (clarithromycin [biaxin], low-dose thalidomide, andexamethasone) for the treatment of myeloma and Waldenstrom’s macroglobulinemia, Leuk Lymph, 2002;43(9):1777-1782.

 

Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after one cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease, J Nucl Med, 2002;43(8):1018-1027.

 

Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R. Treatment of Waldenstrom’s macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol, 2003;30(2):270-274.

 

Leonard JP, Siegel JA, Goldsmith SJ. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: Implications for radioimmunotherapy for patients with non-Hodgkin’s lymphoma, Cancer Invest, 2003;21(2):241-252.

 

Siegel AB, Goldenberg DM, Cesano A, Coleman M, Leonard JP. CD22-directed monoclonal antibody therapy for lymphoma, Semin Oncol, 2003; 30(4):457-464.

 

Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T,

Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties, Clin Cancer Res, 2003; 9(10):3982S-3990S.

 

Navolanic PM, Pui CH, Larson RA, Bishop MR, Pearce TE, Cairo MS, Goldman SC, Jeha SC, Shanholtz CB, Leonard JP, McCubrey JA. ElitekTM-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a meeting report, Dallas TX, January 2002, Leukemia 2003, 17(3):499-514.

 

Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Cesano A, Goldenberg DM. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma, J Clin Oncol, 2003:21(16):3041-3059 (published with editorial comment)

 

Coleman M, Goldenberg DM, Siegel AB, Ketas JC, Fiore JM, Leonard JP Epratuzumab: Targeting B-cell malignancies through CD22, Clin Cancer Res, 2003;9(10):2991S-3994S.

 

Furman RR, Coleman M, Leonard JP. Epratuzumab in non-Hodgkin’sLymphoma. Curr Treat Options Oncol. 2004;5(4):283-8.

 

Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ. The role of FDG-PETin the management of lymphoma. Clin Adv Hematol Oncol. 2004;2:115-121.

Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM. Epratuzumab (humanized anti-CD22 antibody) in aggressive non-Hodgkin’s lymphoma: Phase I/II clinical trial results, Clin Cancer Res, 2004 (10), 5627-34 (published with editorial comment)

 

Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl

R, Kroll S, Coleman M, Goris M, Levy R, Knox S. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res, 2004 (10), 7792-8.

 

Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ. The role of FDG-PETin the management of lymphoma. Clin Adv Hematol Oncol. 2004;2(2):115-21.

Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM, Capizzi RL. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin’s lymphoma treated with tositumomab and Iodine I 131 tositumomab (Bexxar). Blood, 2005 (12):4576-82.

 

Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, Sweetenham J, Alkuzweny B, Finucane DM, Leigh BR. A phase I/II study of Galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol, 2005;23(19):4390-8.

 

Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman R, NiesvizkyR, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WL, Horak ID, Goldenberg DM. Combination antibody therapy with epratuzumab (humanized anti-CD22 antibody) and rituximab (chimeric anti-CD20 antibody) in relapsed/refractory non-Hodgkin’s lymphoma (NHL). J Clin Oncol, 2005:23(22):5044-51.

 

Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, FurmanR, Schuster MW, Muss D, Fiore J, Kroll S, Tidmarsh G, Vallabhajosula S,Goldsmith SJ. Abbreviated chemotherapy with fludarabine followed by Bexxar(tositumomab and Iodine I 131 tositumomab) for untreated follicular lymphoma.  J Clin Oncol, 2005:23(24):5696-704.

 

Fisher RI, Kaminski MS, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Wahl RL, Goldsmith SJ, Coleman M. Tositumomab and Iodine I 131 tositumomab produced durable complete remissions in heavily pretreated patients with low-

grade and transformed low-grade non-Hodgkin’s lymphomas, J Clin Oncol, 2005;23(30):7565-73.

 

Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, Wahl RL. Re-treatment with tositumomab and Iodine I-131 tositumomab in patients with non-Hodgkin’s lymphoma who had previously responded to tositumomab and Iodine I-131 tositumomab, J Clin Oncol, 2005;23(31):7985-93.

 

Leonard JP, Furman RR, Ruan J, Coleman M. New developments in immunotherapy for non-Hodgkin’s lymphoma. Curr Oncol Rep, 2005;7(5):364-71.

 

Leonard JP. Targeting CD20 in follicular NHL: Novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates, Hematology (Am Soc Hematol Educ Program), 2005;335-9.

 

Dosik AD, Coleman M, Kostakoglu L, Furman R, Fiore JM, Kroll S, Stewart P, Vallabhajosula S, Goldsmith SJ, Leonard JP. Subsequent therapy can be administered following tositumomab and iodine-131 tositumomab treatment for non-Hodgkin’s lymphoma, Cancer. 2006;106(3):616-22.

 

Ruan J, Coleman M, Leonard JP. Mantle cell lymphoma: current concepts in biology and treatment. Cancer Treat Res. 2006;131:141-59.

 

Furman RR, Coleman M, Leonard JP. Monoclonal antibodies and radioimmunotherapy for lymphoma. Cancer Treat Res, 2006; 131:221-50.

 

Leonard JP, Furman RR, Coleman M. Proteosome inhibition with bortezomib, a new therapeutic strategy for non-Hodgkin’s lymphoma. Int J. Cancer, 2006; 119(5):971-9.

 

Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiriman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF. Idiotype vaccination induces durable clinical responses in previously treated patients with indolent non-Hodgkin’s lymphoma: A phase II trial, J Clin Oncol, 2006; 24(19):3107-12.

  

Shore T, Harpel J, Schuster MW, Roboz GJ, Leonard JP, Silver RT, Coleman M, Feldman EJ. A study of a reduced intensity conditioning regimen followed by allogeneic stem cell transplant for patients with hematological malignancies using Campath-1H as part of a graft-versus-host disease strategy, Biol Blood Marrow Transplant, 2006; 12(8):868-75. 

 

Siegel AB, Lachs M, Coleman M, Niesvizky R, Leonard JP. Lymphoma in the elderly: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures, Clin Lymphoma Myeloma, 2006; 7(1):65-9. 

 

Ruan J, Hyjek E, Hooper AT, Vincent L, Kermani P, Christos PJ, Ikalowych S, Coleman M, Hempstead B, Leonard JP, Chadburn A, Rafii S. The magnitude of stromal and vascular incorporation of hemangiogenic cells distinguishes histologic subtypes of non-Hodgkin’s lymphoma, Clin Cancer Res, 2006; 12(19):5622-31.

 

Fisher RI, Bernstein S, Kahl BS, Djulbegovic B, Robertson RJ, deVos S,Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O’Connor OA, Shi H, Boral AL, Goy A. Multicenter phase II study of bortezomib in patients with

relapsed or refractory mantle cell lymphoma, J Clin Oncol, 2006; 24(30):4867-74.  

 

Andemariam B and Leonard JP. Should all patients with indolent lymphoma be treated with rituximab maintenance therapy? An overview of the data, Clin Lymphoma Myeloma, 2006 7S1:S20-3

 

Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, Chandramouly A, Verma S, Kothari P, Coleman M. FDG-PET after one cycle of therapy predicts long-term outcome in diffuse large cell lymphoma and classical Hodgkin’s disease, Cancer, 2006; 106(11):2678-87.

 

Emmanouilides C, Kahn KD, Benson DM, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL,Byrd JC, Caligiuri MA. A phase 2 study of rituximab in combination with Recombinant interleukin-2 for rituximab-refractory, indolent non-Hodgkin’s lymphoma. Clin Cancer Res, 2006; 12(23):7046-53.

 

Mones JV, Coleman M, Kostakoglu, Furman RR, Chadburn A, Shore TB,Muss D, Niesvizky R, Kroll S, Vallabhajosula S, Goldsmith SJ, Leonard JP. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin’s lymphoma (NHL) and extensive bone marrow involvement, Leukemia and Lymphoma, 2007; 48(2):342-8.

 

Roboz GJ, Bennett JM, Coleman M, Ritchie EK, Rossi A, Jhaveri K, Feldman EJ, Leonard JP. Myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma, Leukemia Research, 2007; 31(8):1141-4.

 

Leonard JP and Goldenberg DM. Preclinical and clinical evaluation of

epratuzumab (anti-CD22 IgG) in B cell malignancies, Oncogene, 2007;26(25):3704-13.

 

Martin P, Furman R, Coleman M, Leonard JP. Phase I-III studies of anti-B

cell therapy in non-Hodgkin’s lymphoma, Clinical Cancer Research, 2007;13(18):5636s-42s.

 

Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma, Annals of Oncology, 2007;18(7):1216-23.

 

Martin P and Leonard JP. Novel therapeutic targets in mantle cell lymphoma,Expert Opin Ther Targets, 2007;11(7):929-40.

 

Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzilowski J, Zafar F, Mark T, Lent R, Pearse RN, Ely S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoingfront-line lenalidomide and dexamethasone therapy. Br J Haematol. 2007;138(5):640-3.

 

Leonard JP, Friedberg JW, Hagemeister FB, Levine AM. Combination treatment approaches and novel therapies for lymphoma. Clin Adv Hematol Oncol2007;5(8 Suppl 12):4-20.   

 

 iesvizky R, Martanez-Baaos D, Jalbrzikowski J, Christos PJ, Furst JR, DeSancho MT, Mark TM, Pearse RN, Mazumdar M, Zafar F, Pekle K, Rambo A, Leonard JP, et al. Prophylactic low-dose aspirin is effective anti-thrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma, Leukemia and Lymphoma, 2007;48(12):2330-7. 

 

Leonard JP, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Link B, Sparano J, Tsai D, Horning SJ, Kurman M, Krieg AM and Weiner GJ. A phase I trial of TLR9 agonist PF-3512676 (CpG 7909) in Relapsed or refractory non-Hodgkin’s lymphoma patients with or afterRituximab, Clinical Cancer Research, 2007;13(20):6168-74. 

 

Niesvizky R, Christos PJ, Jayabalan DS, Furst JR, Cho HJ, Pearse RN, Zafar F, Pekle K, Lent R, Ely S, Jin DK, Shore T, Tepler J, Harpel J, SchusterM, Mathew S, Leonard JP, Rafii S, Chen-Kiang S, Mazumdar M, Coleman M.BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/Dexamethasone)combination therapy results in high complete and overall response rates in treatment-naïve symptomatic multiple myeloma patients, Blood, 2008;111(3):1101-9. 

 

Bartlett N, Younes A, Carabasi M, Forero A, Rosenblatt J, Leonard JP

Bernstein S, Bociek RG, Barton J.    A phase I multi-dose study of SGN-30

immunotherapy in patients with refractory or recurrent CD30 hematologic

malignancies, Blood, 2008; 114(4):1848-54. 

 

Blinder VS, Chadburn A, Furman R, Mathew S, and Leonard JP. Improving outcomes for patients with Burkitt’s lymphoma and human immunodeficiency virus, AIDS Patient Care and STDs. 2008;22(3):175-87. 

 

Coleman M, Martin P, Ruan J, Furman RR, Niesvizky R, Elstrom R, George P,

Leonard JP, Kaufman TP. Low dose metronomic multidrug therapy with the PEP-C (Prednisone, Etoposide, Procarbazine and Cyclophosphamide) oral combination chemotherapy regimen for mantle cell lymphoma, Leukemia and Lymphoma, 2008; 49(3):447-50. 

 

Coleman M, Martin P, Ruan J, Furman RR, Niesvizky R, Elstrom R, George P,Kaufman TP, Leonard JP. The PEP-C (Prednisone, Etoposide, Procarbazine, and Cyclophosphamide) oral combination chemotherapy regimen for relapsingand refractory lymphoma: Low dose, metronomic, multidrug therapy. Cancer, 2008:112(10):2228-32.  

 

Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E,Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S,Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overallsurvival exceeding 7 years with standard therapies. Ann Oncol. 2008; 19(7):1327-30. 

 

Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, ColemanM, Leonard JP. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin’s lymphoma. Semin Hematol 2008; 45(2):126-32. 

 

Rutherford SC, Andemariam B, Philips SM, Elstrom RL, Chadburn A, FurmanRR, Niesvizky R, Martin P, Fahey TJ, Coleman M, Goldsmith SJ, Leonard JP. FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leuk Lymphoma. 2008; 49(4):719-26.  

 

Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A, Pearse RN, Harpel J, Shore T, Schuster MW, Leonard JP, Christos PJ, Coleman M, Niesvizky R. stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008; 14(7):795-8.  

 

Elstrom RL, Leonard JP, Coleman M, Brown RK. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnosticcontrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 2008;19(10):1770-3. 

 

Lin A, Kadam JS, Bodenheimer HC, Leonard J, Joyce MA, Lake-Bakaar G. Concomitant diffuse large B-cell lymphoma and hepatocellular carcinoma in Chronic hepatitis C virus liver disease: a study of two cases. J Med Virol. 2008; 80(8):1350-3. 

 

Leonard JP, Gregory SA, Maloney DG, Vose JM, Younes A, Zelenetz AD. Optimizing the treatment of patients with rituximab-pretreated recurrent indolentnon-Hodgkin’s lymphoma. Clin Adv Hematol Oncol. 2008; 6(6):437-45. 

 

Leonard JP, Martin P, Ruan J, Elstrom R, Barrientos J, Coleman M, FurmanRR. New monoclonal antibodies for non-Hodgkin’s lymphoma. Ann Oncol. 2008;19 suppl 4:iv60-2.

 

Yang C, Lu P, Lee FY, Chadburn A, Barrientos JC, Leonard JP, Ye F,

Zhang D, Knowles DM, Wang YL.  Tyrosine kinase inhibition in diffuse large B-

cell lymphoma: molecular basis for antitumor activity and drug resistance of

dasatinib. Leukemia. 2008; 22(9):1755-66. 

 

Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-

Hodgkin’s lymphoma. New England Journal of Medicine 2008; 359(6):613-26. 

 

Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, Coleman M, Goldenberg DM. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international, multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer

2008 Nov 15;113(10):2714-23.

 

Leonard JP, Martin P, Barrientos J, Elstrom R. Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol. 2008 Jul;45(3 Suppl2):S11-6. 

 

Elstrom RL, Martin P, Leonard JP. New biologic agents and immunologic strategies. Hematol Oncol Clin North Am. 2008 Oct;22(5):1037-49.  

 

Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL, Lent R, Christos PJ,

Lee JW, Agrawal YP, Matthew S, Ely S, Mazumdar M, Cesarman E, Leonard JP,

Furman RR, Chen-Kiang S, Niesvizky R. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol. 2008 Dec;143(5):654-60. 

 

Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and antiangiogenic therapy in non-Hodgkin’s lymphoma. Ann Oncol. 2009 Mar;20(3):413-24.

 

Goy A, Bernstein SH, Kahl BS, Bjulbegovic B, Robertson MJ, deVos S, Epner E, Krishnan A, Leonard JP, Lonial S, Nasta S, O’Connor OA, Shi H, Boral AL, Fisher RI. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009 Mar;20(3):520-5.

 

Mark T, Martin P, Leonard JP, Niesvizky R. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2009 Jan;18(1):99-104.

 

Elstrom RL, Martin P, Leonard JP. New biologic agents and immunologic strategies. Hematol Oncol Clin North Am. 2008 Oct;22(5):1037-49. 

 

Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R,

Nisevizky R, Ely S, DiLiberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman

M, Leonard JP. Outcome of deferred initial therapy (“watch and wait”) in mantle cell lymphoma. Journal of Clinical Oncology, 2009 Mar 10;27(8):1209-13.

 

Martin P, Leonard JP, Coleman M, Furman RR. Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. Clin Lymphoma Myeloma. 2009 Jun;9(3):247-9).

 

Ruan J, Coleman M, Leonard JP. Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology. 2009 Jul;23(8):683-90.

 

Hasan A, Michel M, Patel V, Stasi R, Cunningham-Rundles S, Leonard JP, Bussel J. Repeated courses of rituximab in chronic ITP: Three different regimens. Am J Hematol. 2009 Jul 25 epub ahead of print.

 

Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, Bosly A, Pinter-Brown L, Kennedy D, Sievers EL, Gopal AK. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009 Jul;146(2):171-9. 

 

Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II results. Journal of Clinical Oncology. 2009 Jul 10;27(20):3346-53.

 

Leonard JP, Williams ME, Goy A, Grant S, Pfreundschuh M, Rosen ST, Sweetenham JW. Mantle cell lymphoma: biological insights and treatment advances. Clin Lymphoma Myeloma. 2009 Aug;9(4):267-77.

 

 

 

 

 

 

Back to topBack To Top